HK1200095A1 - Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof - Google Patents
Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereofInfo
- Publication number
- HK1200095A1 HK1200095A1 HK15100523.9A HK15100523A HK1200095A1 HK 1200095 A1 HK1200095 A1 HK 1200095A1 HK 15100523 A HK15100523 A HK 15100523A HK 1200095 A1 HK1200095 A1 HK 1200095A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- bendamustine
- formulations
- combination
- histone deacetylase
- deacetylase inhibitor
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2011/051470 WO2013039488A1 (en) | 2011-09-13 | 2011-09-13 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1200095A1 true HK1200095A1 (en) | 2015-07-31 |
Family
ID=47883567
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK15100523.9A HK1200095A1 (en) | 2011-09-13 | 2015-01-16 | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US9492423B2 (xx) |
| EP (1) | EP2755648B1 (xx) |
| JP (1) | JP6330118B2 (xx) |
| KR (1) | KR101892788B1 (xx) |
| CN (1) | CN103917231B (xx) |
| AU (1) | AU2011376953B2 (xx) |
| CA (1) | CA2845806C (xx) |
| ES (1) | ES2627820T3 (xx) |
| HK (1) | HK1200095A1 (xx) |
| MX (1) | MX365393B (xx) |
| NZ (1) | NZ621221A (xx) |
| RU (1) | RU2609833C2 (xx) |
| SG (1) | SG2014014419A (xx) |
| UA (1) | UA110853C2 (xx) |
| WO (1) | WO2013039488A1 (xx) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2099442T3 (en) | 2006-12-26 | 2015-02-16 | Pharmacyclics Inc | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| MX365393B (es) | 2011-09-13 | 2019-05-31 | Pharmacyclics Llc | Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas. |
| TWI573792B (zh) | 2012-02-01 | 2017-03-11 | 歐陸斯迪公司 | 新穎治療劑 |
| GB201409471D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409485D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| GB201409488D0 (en) | 2014-05-28 | 2014-07-09 | Euro Celtique Sa | Pharmaceutical composition |
| CN107438436A (zh) * | 2014-12-05 | 2017-12-05 | 摩德纳和雷焦艾米利亚大学 | 用于治疗淋巴瘤的组蛋白脱乙酰酶抑制剂和苯达莫司汀的组合 |
| EP3310168A4 (en) * | 2015-06-19 | 2019-03-06 | Trustees of Boston University | METHODS AND COMPOSITIONS FOR TREATING CONDITIONS INDUCED BY HERPETIC VIRUS |
| US20200179381A1 (en) * | 2016-04-08 | 2020-06-11 | Cereno Scientific Ab | Compounds and compositions for the treatment or prevention of pathological conditions associated with excess fibrin deposition and/or thrombus formation |
| WO2017182611A1 (en) * | 2016-04-21 | 2017-10-26 | Valcuria Ab | Composition and method for pretreating cancer |
| CA3040155C (en) | 2016-10-11 | 2024-01-16 | Euro-Celtique S.A. | Compound for use in the treatment of hodgkin lymphoma |
| SG10201609137PA (en) * | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Gamma-polyglutamic acid and zinc compositions |
| SG10201609131YA (en) | 2016-11-01 | 2018-06-28 | Xylonix Ip Holdings Pte Ltd | Zinc-pga compositions and methods for treating cancer |
| GB201706544D0 (en) | 2017-04-25 | 2017-06-07 | Plasticell Ltd | Method |
| GB201709402D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating t-pll |
| GB201709405D0 (en) | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating ovarian cancer |
| GB201709403D0 (en) * | 2017-06-13 | 2017-07-26 | Euro Celtique Sa | Compounds for treating sarcoma |
| GB201709406D0 (en) | 2017-06-13 | 2017-07-26 | Euro-Cletique S A | Compounds for treating TNBC |
| KR102338992B1 (ko) * | 2018-01-05 | 2021-12-14 | 지엔티 바이오테크 & 메디컬즈 코포레이션 | 종양 미세환경 및 면역요법의 조절을 위한 약제학적 조합물 및 방법 |
| EP3976198A4 (en) | 2019-05-31 | 2023-07-19 | Viracta Subsidiary, Inc. | METHODS OF TREATMENT OF VIRAL ASSOCIATED CANCER WITH HISTONE DEACETYLASE INHIBITORS |
| WO2022159852A1 (en) * | 2021-01-25 | 2022-07-28 | Icahn School Of Medicine At Mount Sinai | Methods and compositions for treating adenoid cystic carcinoma |
Family Cites Families (100)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3126375A (en) | 1964-03-24 | Chioacyl | ||
| US2789118A (en) | 1956-03-30 | 1957-04-16 | American Cyanamid Co | 16-alpha oxy-belta1, 4-pregnadienes |
| US2990401A (en) | 1958-06-18 | 1961-06-27 | American Cyanamid Co | 11-substituted 16alpha, 17alpha-substituted methylenedioxy steroids |
| US3048581A (en) | 1960-04-25 | 1962-08-07 | Olin Mathieson | Acetals and ketals of 16, 17-dihydroxy steroids |
| US3749712A (en) | 1970-09-25 | 1973-07-31 | Sigma Tau Ind Farmaceuti | Triamcinolone acetonide esters and process for their preparation |
| BE794063A (fr) | 1972-01-17 | 1973-07-16 | Henkel & Cie Gmbh | Anti-inflammatoires pour compositions cosmetiques |
| SE378110B (xx) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| SE378109B (xx) | 1972-05-19 | 1975-08-18 | Bofors Ab | |
| US3996359A (en) | 1972-05-19 | 1976-12-07 | Ab Bofors | Novel stereoisomeric component A of stereoisomeric mixtures of 2'-unsymmetrical 16,17-methylenedioxy steroid 21-acylates, compositions thereof, and method of treating therewith |
| US3775656A (en) | 1972-05-22 | 1973-11-27 | Aviat Inc | Platform stabilization system |
| CH581818A5 (xx) | 1973-02-27 | 1976-11-15 | Cierva Juan J De | |
| US4327725A (en) | 1980-11-25 | 1982-05-04 | Alza Corporation | Osmotic device with hydrogel driving member |
| EP0084236A3 (en) | 1981-12-22 | 1983-08-03 | Fbc Limited | Fungicidal heterocyclic compounds and compositions containing them |
| US4498038A (en) | 1983-02-15 | 1985-02-05 | Malueg Richard M | Stabilization system for soft-mounted platform |
| US4624848A (en) | 1984-05-10 | 1986-11-25 | Ciba-Geigy Corporation | Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use |
| GB8518301D0 (en) | 1985-07-19 | 1985-08-29 | Fujisawa Pharmaceutical Co | Hydrodynamically explosive systems |
| EP0230654B1 (en) | 1985-12-28 | 1992-03-18 | Sumitomo Pharmaceuticals Company, Limited | Sustained pulsewise release pharmaceutical preparation |
| US4968509A (en) | 1987-07-27 | 1990-11-06 | Mcneilab, Inc. | Oral sustained release acetaminophen formulation and process |
| DE3889545T2 (de) | 1987-10-20 | 1994-10-13 | Otsuka Pharma Co Ltd | Phenylcarbonsäure-abkömmlinge. |
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5612059A (en) | 1988-08-30 | 1997-03-18 | Pfizer Inc. | Use of asymmetric membranes in delivery devices |
| IL92966A (en) | 1989-01-12 | 1995-07-31 | Pfizer | Hydrogel-operated release devices |
| JPH03215470A (ja) | 1990-01-22 | 1991-09-20 | Suntory Ltd | プロピオン酸アミド誘導体，その製造法及びそれを有効成分として含有する除草剤 |
| US5017381A (en) | 1990-05-02 | 1991-05-21 | Alza Corporation | Multi-unit pulsatile delivery system |
| KR0182801B1 (ko) | 1991-04-16 | 1999-05-01 | 아만 히데아키 | 고체 분산체의 제조방법 |
| DE4124345A1 (de) | 1991-07-23 | 1993-01-28 | Gruenenthal Gmbh | Substituierte 3,4-dihydronaphthaline, diese verbindungen enthaltende arzneimittel und verfahren zur herstellung dieser verbindungen und arzneimittel |
| WO1993009785A1 (en) | 1991-11-22 | 1993-05-27 | Procter & Gamble Pharmaceuticals, Inc. | Risedronate delayed-release compositions |
| US5229135A (en) | 1991-11-22 | 1993-07-20 | Prographarm Laboratories | Sustained release diltiazem formulation |
| US5461140A (en) | 1992-04-30 | 1995-10-24 | Pharmaceutical Delivery Systems | Bioerodible polymers for solid controlled release pharmaceutical compositions |
| US5260068A (en) | 1992-05-04 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Multiparticulate pulsatile drug delivery system |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| CA2147283C (en) | 1992-10-16 | 2007-01-16 | Kouichi Nakamichi | Method of manufacturing wax matrices |
| US5260069A (en) | 1992-11-27 | 1993-11-09 | Anda Sr Pharmaceuticals Inc. | Pulsatile particles drug delivery system |
| US5686105A (en) | 1993-10-19 | 1997-11-11 | The Procter & Gamble Company | Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery |
| DE4327365A1 (de) | 1993-08-14 | 1995-02-16 | Boehringer Mannheim Gmbh | Verwendung von Phenolen und Phenolderivaten als Arzneimittel mit fibrinogensenkender Wirkung |
| US5448938A (en) | 1993-10-18 | 1995-09-12 | Guardian Technologies International, Inc. | Removable ballistic resistant armor seat cover and floor mat |
| US5567441A (en) | 1995-03-24 | 1996-10-22 | Andrx Pharmaceuticals Inc. | Diltiazem controlled release formulation |
| CA2220451A1 (en) | 1995-05-17 | 1996-11-21 | Cedars-Sinai Medical Center | Methods and compositions for improving digestion and absorption in the small intestine |
| US5798119A (en) | 1995-06-13 | 1998-08-25 | S. C. Johnson & Son, Inc. | Osmotic-delivery devices having vapor-permeable coatings |
| US5837284A (en) | 1995-12-04 | 1998-11-17 | Mehta; Atul M. | Delivery of multiple doses of medications |
| US5958957A (en) | 1996-04-19 | 1999-09-28 | Novo Nordisk A/S | Modulators of molecules with phosphotyrosine recognition units |
| US5840329A (en) | 1997-05-15 | 1998-11-24 | Bioadvances Llc | Pulsatile drug delivery system |
| US6211197B1 (en) | 1998-10-07 | 2001-04-03 | Merck Frosst Canada & Co. | Prostaglandin receptor ligands |
| US6395300B1 (en) | 1999-05-27 | 2002-05-28 | Acusphere, Inc. | Porous drug matrices and methods of manufacture thereof |
| US6718130B2 (en) | 1999-05-28 | 2004-04-06 | David E. Grober | Stabilized camera and marker buoy for media coverage of aquatic events |
| JP2003500772A (ja) | 1999-05-28 | 2003-01-07 | グロバー、デイビッド、イー | 自主的なセルフレベリング自動修正式安定台 |
| CA2379608A1 (en) | 1999-08-10 | 2001-02-15 | Pangene Corporation | Cancer treatments and diagnostics utilizing rad51 related molecules and methods |
| AU6936500A (en) | 1999-08-24 | 2001-03-19 | Regents Of The University Of California, The | Non-quinoline inhibitors of malaria parasites |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| DK1212327T3 (da) | 1999-09-17 | 2003-12-15 | Abbott Gmbh & Co Kg | Pyrazolopyrimidiner som terapeutiske midler |
| EP1233958B1 (en) | 1999-11-23 | 2011-06-29 | MethylGene Inc. | Inhibitors of histone deacetylase |
| BR0113626A (pt) | 2000-08-30 | 2003-06-17 | Pfizer Prod Inc | Formulações de liberação sustentada para secretores de hormÈnio do crescimento |
| WO2002030879A2 (en) | 2000-09-29 | 2002-04-18 | Prolifix Limited | Carbamic acid compounds comprising a sulfonamide linkage as hdac inhibitors |
| GB0023983D0 (en) | 2000-09-29 | 2000-11-15 | Prolifix Ltd | Therapeutic compounds |
| KR100589032B1 (ko) | 2000-10-20 | 2006-06-14 | 에자이 가부시키가이샤 | 질소 함유 방향환 유도체 |
| JP2004527229A (ja) | 2000-12-28 | 2004-09-09 | エピダウロス バイオテクノロジー アクツィエンゲゼルシャフト | 多型ｃｙｐ３ａ５発現の遺伝的決定基の同定 |
| MXPA01013172A (es) | 2001-02-14 | 2002-08-21 | Warner Lambert Co | Inhibidores sulfonamida de metaloproteinasa de matriz. |
| US6465014B1 (en) | 2001-03-21 | 2002-10-15 | Isp Investments Inc. | pH-dependent sustained release, drug-delivery composition |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| PT1404304E (pt) | 2001-06-28 | 2009-06-26 | Ucb Farchim Sa | Comprimido contendo cetirizina e pseudoefedrina |
| US7247426B2 (en) | 2001-08-02 | 2007-07-24 | Agilent Technologies, Inc. | Classifying cancers |
| ITMI20011733A1 (it) | 2001-08-07 | 2003-02-07 | Italfarmaco Spa | Derivati dell'acido idrossamico inibitori degli enzimi istone deacetilasi, quali nuovi farmaci antiinfiammatori inibenti la sintesi di citoc |
| JP4238728B2 (ja) | 2001-08-21 | 2009-03-18 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の医薬用途ならびにその抗腫瘍効果の評価方法 |
| US20040142325A1 (en) | 2001-09-14 | 2004-07-22 | Liat Mintz | Methods and systems for annotating biomolecular sequences |
| US20030166026A1 (en) | 2002-01-09 | 2003-09-04 | Lynx Therapeutics, Inc. | Identification of specific biomarkers for breast cancer cells |
| AU2003244498A1 (en) | 2002-02-04 | 2003-09-02 | Epidauros Biotechnologie Ag | Polymorphisms in the human gene for tpmt and their use in diagnostic and therapeutic applications |
| WO2003070691A1 (fr) | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | Derive de n-hydroxycarboxamide |
| US20040132825A1 (en) | 2002-03-04 | 2004-07-08 | Bacopoulos Nicholas G. | Methods of treating cancer with HDAC inhibitors |
| EP1525199A1 (en) | 2002-08-02 | 2005-04-27 | Argenta Discovery Limited | Substituted thienyl-hydroxamic acids as histone deacetylase inhibitors |
| EP1400806A1 (en) | 2002-09-18 | 2004-03-24 | G2M Cancer Drugs AG | The use of molecular markers for the preclinical and clinical profiling of inhibitors of enzymes having histone deacetylase activity |
| US6769347B1 (en) | 2002-11-26 | 2004-08-03 | Recon/Optical, Inc. | Dual elevation weapon station and method of use |
| JPWO2004074478A1 (ja) | 2003-02-19 | 2006-06-01 | アステラス製薬株式会社 | ヒストンデアセチラーゼ阻害剤の抗腫瘍効果の予測方法 |
| GB0303910D0 (en) | 2003-02-20 | 2003-03-26 | Merck Sharp & Dohme | Therapeutic agents |
| US7169801B2 (en) | 2003-03-17 | 2007-01-30 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
| EP1611088B1 (en) | 2003-04-07 | 2009-06-17 | Pharmacyclics, Inc. | Hydroxamates as therapeutic agents |
| ZA200507751B (en) * | 2003-04-07 | 2007-01-31 | Axys Pharm Inc | Novel hydroxamates as therapeutic agents |
| PE20050206A1 (es) | 2003-05-26 | 2005-03-26 | Schering Ag | Composicion farmaceutica que contiene un inhibidor de histona deacetilasa |
| EP2263694B1 (en) | 2003-09-25 | 2013-06-12 | Astellas Pharma Inc. | Antitumor agent comprising the histone deacetylase inhibitor FK228 and the topoisomerase II inhibitor doxorubicin |
| US20070099190A1 (en) | 2003-11-04 | 2007-05-03 | Martin Dugas | Method for distinguishing leukemia subtypes |
| JP2007513635A (ja) | 2003-12-12 | 2007-05-31 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 遺伝子発現プロファイルおよび使用方法 |
| US8019552B2 (en) | 2004-03-05 | 2011-09-13 | The Netherlands Cancer Institute | Classification of breast cancer patients using a combination of clinical criteria and informative genesets |
| GB2427405A (en) | 2004-04-07 | 2006-12-27 | Pharmacyclics Inc | Novel hydroxamates as therapeutic agents |
| EP1591109B1 (en) | 2004-04-30 | 2008-07-02 | TopoTarget Germany AG | Formulation comprising histone deacetylase inhibitor exhibiting biphasic release |
| BRPI0511065A (pt) | 2004-06-04 | 2007-12-26 | Pfizer Prod Inc | método para tratar crescimento de célula anormal |
| CA2575557A1 (en) | 2004-07-30 | 2006-02-09 | Rosetta Inpharmatics Llc | Prognosis of breast cancer patients |
| US20080248506A1 (en) | 2004-10-07 | 2008-10-09 | Pharmacyclics, Inc. | Method of Monitoring Anti-Tumor Activity of an Hdac Inhibitor |
| WO2006065392A2 (en) * | 2004-11-05 | 2006-06-22 | Cephalon, Inc. | Cancer treatments |
| US8436190B2 (en) * | 2005-01-14 | 2013-05-07 | Cephalon, Inc. | Bendamustine pharmaceutical compositions |
| WO2006101454A1 (en) | 2005-03-21 | 2006-09-28 | S*Bio Pte Ltd | Benzothiophene derivatives: preparation and pharmaceutical applications |
| WO2007109178A2 (en) | 2006-03-16 | 2007-09-27 | Pharmacyclics, Inc. | Indole derivatives as inhibitors of histone deacetylase |
| JP5185274B2 (ja) | 2006-09-15 | 2013-04-17 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | プロテアソームインヒビターと組み合わせてクラスｉおよびクラスｉｉｂヒストンデアセチラーゼに対する組み合わせ活性を持つヒストンデアセチラーゼインヒビター |
| DK2099442T3 (en) | 2006-12-26 | 2015-02-16 | Pharmacyclics Inc | Method of using histone deacetylase inhibitors and monitoring biomarkers in combination therapy |
| EP2993473A1 (en) | 2007-01-30 | 2016-03-09 | Pharmacyclics, Inc. | Methods for determining cancer resistance to histone deacetylase inhibitors |
| EP2060565A1 (en) | 2007-11-16 | 2009-05-20 | 4Sc Ag | Novel bifunctional compounds which inhibit protein kinases and histone deacetylases |
| EP2110377A1 (en) * | 2008-04-15 | 2009-10-21 | DAC S.r.l. | Spirocyclic derivatives as histone deacetylase inhibitors |
| US8603521B2 (en) | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| UY34295A (es) | 2011-09-08 | 2013-04-30 | Servier Lab | Nuevo esquema de administración de la n-hidroxi -4- {2-[3- (n,ndimetilaminometil)benzofuran -2- ilcarbonilamino]etoxi}benzamida |
| MX365393B (es) | 2011-09-13 | 2019-05-31 | Pharmacyclics Llc | Formulaciones de inhibidor de histona deacetilasa en combinación con bendamustina y usos de las mismas. |
| AR097204A1 (es) | 2013-08-02 | 2016-02-24 | Pharmacyclics Inc | Métodos de tratamiento de tumores sólidos |
-
2011
- 2011-09-13 MX MX2014002942A patent/MX365393B/es active IP Right Grant
- 2011-09-13 RU RU2014111069A patent/RU2609833C2/ru not_active IP Right Cessation
- 2011-09-13 JP JP2014530636A patent/JP6330118B2/ja active Active
- 2011-09-13 AU AU2011376953A patent/AU2011376953B2/en active Active
- 2011-09-13 UA UAA201402905A patent/UA110853C2/uk unknown
- 2011-09-13 EP EP11872389.9A patent/EP2755648B1/en active Active
- 2011-09-13 NZ NZ621221A patent/NZ621221A/en not_active IP Right Cessation
- 2011-09-13 CN CN201180074826.7A patent/CN103917231B/zh active Active
- 2011-09-13 WO PCT/US2011/051470 patent/WO2013039488A1/en active Application Filing
- 2011-09-13 ES ES11872389.9T patent/ES2627820T3/es active Active
- 2011-09-13 US US14/344,314 patent/US9492423B2/en active Active
- 2011-09-13 CA CA2845806A patent/CA2845806C/en active Active
- 2011-09-13 KR KR1020147007117A patent/KR101892788B1/ko active IP Right Grant
- 2011-09-13 SG SG2014014419A patent/SG2014014419A/en unknown
-
2015
- 2015-01-16 HK HK15100523.9A patent/HK1200095A1/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ES2627820T3 (es) | 2017-07-31 |
| MX2014002942A (es) | 2014-09-15 |
| UA110853C2 (uk) | 2016-02-25 |
| EP2755648B1 (en) | 2017-03-08 |
| CN103917231A (zh) | 2014-07-09 |
| EP2755648A1 (en) | 2014-07-23 |
| US9492423B2 (en) | 2016-11-15 |
| RU2609833C2 (ru) | 2017-02-06 |
| NZ621221A (en) | 2016-07-29 |
| US20140341989A1 (en) | 2014-11-20 |
| KR101892788B1 (ko) | 2018-08-28 |
| WO2013039488A1 (en) | 2013-03-21 |
| CA2845806C (en) | 2019-06-11 |
| CA2845806A1 (en) | 2013-03-21 |
| AU2011376953B2 (en) | 2017-08-24 |
| SG2014014419A (en) | 2014-07-30 |
| AU2011376953A1 (en) | 2014-03-06 |
| JP6330118B2 (ja) | 2018-05-30 |
| CN103917231B (zh) | 2016-09-28 |
| KR20140073503A (ko) | 2014-06-16 |
| EP2755648A4 (en) | 2015-03-11 |
| MX365393B (es) | 2019-05-31 |
| RU2014111069A (ru) | 2015-10-20 |
| JP2014526503A (ja) | 2014-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1200095A1 (en) | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof | |
| HRP20180953T1 (hr) | Supstituirani 3-haloalilaminski inhibitori za ssao i njihove uporabe | |
| EP2678018A4 (en) | COMBINATION OF CHINESE HEMMER AND USES THEREOF | |
| HK1173440A1 (en) | N-(imidazopyrimidin-7-yl)-heteroarylamide derivatives and their use as pde10a inhibitors n-(-7-)- pde10a | |
| EP2696682A4 (en) | MIF-HEMMER AND USES THEREOF | |
| HK1202244A1 (en) | Prebiotic formulations and methods of use | |
| EP2592933A4 (en) | MIF INHIBITORS AND USES THEREOF | |
| HK1198827A1 (en) | Dyrk1 inhibitors and uses thereof dyrk1 | |
| IL227379A0 (en) | Histone deacetylase inhibitors and compositions and methods of using them | |
| EP2563372A4 (en) | PREBIOTIC FORMULATIONS AND METHODS OF USE | |
| IL257069B (en) | Inhibitors of cell death and uses thereof | |
| IL214244A (en) | Diastylase Heisone Inhibitors and their use in healing | |
| EP2536709A4 (en) | PROLYLHYDROXYLASE INHIBITORS AND METHODS OF USE | |
| HK1204998A1 (en) | Combinations of histone deacetylase inhibitor and pazopanib and uses thereof | |
| IL236686A0 (en) | Inhibitors of histone deacetylase and compositions and methods of using them | |
| IL223514A0 (en) | Benzamide derivatives and their use as hsp90 inhibitors | |
| EP2725013A4 (en) | NEW HISTONDEACETYLASE INHIBITORS FROM BENZAMIDES AND THEIR USE | |
| SG10201607620YA (en) | Formulations of histone deacetylase inhibitor in combination with bendamustine and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| CORR | Corrigendum |
Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF 20180302: (54) FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF |
|
| CORR | Corrigendum |
Free format text: CORRECTED DATA OF SECTION 27 TO JOURNAL OF 20180302: (54) FORMULATIONS OF HISTONE DEACETYLASE INHIBITOR IN COMBINATION WITH BENDAMUSTINE AND USES THEREOF |